EFPIA calls for reset to revive Europe’s role in global life sciences

30 June 2025

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has appointed Bayer’s (BAYN: DE) Stefan Oelrich as its new president, with Roche (ROG: SIX) chief executive Teresa Graham and Almirall’s (BME: ALM) Carlos Gallardo taking on first and second vice president roles.

The new leadership team made its debut at a press event in Brussels on June 26, setting out an ambitious agenda to reposition Europe as a global leader in medical innovation. They warned that without swift and bold policy shifts, the region risks falling further behind the USA and China in attracting biopharma investment and delivering next-generation treatments.

The region is said to be a crossroads, amid a changing economic and regulatory landscape globally, and EFPIA’s warning comes amid mounting concern that Europe is losing ground in life sciences.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK